WHERE THE EVIDENCE STANDS
Research interest centres on wound healing, angiogenesis and muscle repair, with evidence from cell and animal studies. Published human trial data on the fragment itself are scarce; most human work concerns the full-length thymosin beta-4 protein in other settings.
TB-500 was placed in Category 2 in September 2023 and was among the six substances the FDA's advisory committee recommended for the 503A bulks list in July 2026, by 8 votes to 6. It is often promoted alongside BPC-157, a pairing named in a Harvard Chan School explainer of October 2026.
ENTRIES ABOUT TB-500 · 3
PUBLIC
A 1 October 2026 Q&A from the Harvard T.H. Chan School of Public Health lists BPC-157, TB-500, MOTS-c, CJC-1295 and ipamorelin among synthetic peptides promoted online for recovery and performance.
REGULATION
On 23–24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, epitalon and Semax for the 503A bulks list. Emideltide was not recommended.
REGULATION
In September 2023 the FDA placed nineteen peptides in Category 2. In April 2026 it removed twelve of them after their nominations were withdrawn and scheduled advisory meetings to consider adding them to the 503A bulks list.
SOURCES
- Restore Health Consulting. FDA adds several peptides to Category 2 bulks list (list of 2023 additions). 2026. Secondary summary. https://www.restorehealthconsulting.com/news/fda-adds-several-peptides-to-category-2-bulks-list-restricting-them-from-compounding
- NCPA. FDA advisory committee nominates six peptides for pharmacies to compound. 31 Jul 2026. News report. https://ncpa.org/newsroom/qam/2026/07/31/fda-advisory-committee-nominates-six-peptides-pharmacies-compound
REVIEWED 5 Oct 2026 · NEXT REVIEW JAN 2027 · CORRECTIONS ARE LOGGED HERE